Item 2.02 Results of Operations and Financial Condition.

As discussed in Item 8.01 of this Current Report on Form 8-K, IGM Biosciences, Inc. (the "Company") updated its corporate presentation and disclosed that the Company had an estimated cash and investments balance of $427.2 million as of December 31, 2022 (unaudited).

Item 8.01 Other Events.

The Company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California from January 9-12, 2023.

A copy of the Company's updated corporate presentation is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit     Description
99.1          IGM Biosciences, Inc. Corporate Presentation
104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses